Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/20/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Illana Gozes

Wrong Dr. Illana Gozes?

Director of Adams Super Center fo...

Phone: (212) ***-****  HQ Phone
Email: i***@***.il
Local Address: Tel Aviv, Israel
Tel Aviv University
39 Broadway Suite 1510
New York, New York 10006
United States

Company Description: Founded in 1963, Tel Aviv University is one of Israel's foremost research and teaching universities.
Background

Employment History

  • Member, Sackler Faculty
    Tel Aviv University
  • Chief Scientific Officer
    Allon Therapeutics Inc.
  • Professor of Clinical Biochemistry
    Sackler
  • Member, Faculty of Medicine
    Sackler
  • Chief
    Journal of Molecular Neuroscience
  • Editor-in-Chief
    Journal of Molecular Neuroscience
  • President
    Israel Society for Neuroscience

Board Memberships and Affiliations

Education

  • PhD
    Tel Aviv University
  • Ph.D.
    The Weizmann Institute of Science
  • BSc
    Tel Aviv University
  • PhD
    The Weizmann Institute of Science
144 Total References
Web References
In the News - CFTAU
www.cftau.org, 20 July 2014 [cached]
Now, Prof. Illana Gozes - the Lily and Avraham Gildor Chair for the Investigation of Growth Factors, the director of the Adams Super Center for Brain Studies at the Sackler Faculty of Medicine, and a member of the Sagol School of Neuroscience at Tel Aviv University - has discovered that an important cell-maintenance process called autophagy is reduced in the brains of schizophrenic patients. The findings, published this week in Nature's Molecular Psychiatry, advance the understanding of schizophrenia and could enable the development of new diagnostic tests and drug treatments for the disease.
"We discovered a new pathway that plays a part in schizophrenia," said Prof. Gozes.
...
Brain-cell death also occurs in schizophrenics, so Prof. Gozes and her colleagues set out to see if blocked autophagy could be involved in the progression of that condition as well. They found RNA evidence of decreased levels of the protein beclin 1 in the hippocampus of schizophrenia patients, a brain region central to learning and memory. Beclin 1 is central to initiating autophagy - its deficit suggests that the process is indeed blocked in schizophrenia patients. The researchers say that developing drugs to boost beclin 1 levels and restart autophagy could offer a new way to treat schizophrenia.
"It is all about balance," said Prof Gozes. "Paucity in beclin 1 may lead to decreased autophagy and enhanced cell death. Our research suggests that normalizing beclin 1 levels in schizophrenia patients could restore balance and prevent harmful brain-cell death."
Next, the researchers looked at protein levels in the blood of schizophrenia patients. They found no difference in beclin 1 levels, suggesting that the deficit is limited to the hippocampus. This said, the researchers also found increased levels of another protein, activity-dependent neuroprotective protein (ADNP), discovered by Prof. Gozes and shown to be essential for brain formation and function, in the patients' white blood cells.
...
Prof. Gozes discovered ADNP in 1999 and carved a protein fragment, NAP, from it. NAP mimics the protein nerve cell protecting properties. In follow-up studies Prof. Gozes helped develop the drug candidate davunetide (NAP). In Phase II clinical trials, davunetide (NAP) improved the ability of schizophrenic patients to cope with daily life. A recent collaborative effort by Prof. Gozes and Dr. Sandra Cardoso and Dr. Raquel Esteves showed that NAP improved autophagy in cultures of brain-like cells.
...
Now Prof. Illana Gozes of Tel Aviv University's Sackler Faculty of Medicine has developed a new peptide in her lab, called NAP or Davunetide, which has the capacity to both protect and restore microtubule function. The peptide is a compound derived from the protein ADNP, which regulates more than 400 genes and is essential for brain formation, memory, and behaviour.
Prof. Gozes and her team of researchers, including Dr. Yan Jouroukhin and graduate student Regin Ostritsky of TAU, observed that in animal models with microtubule damage, NAP was able to maintain or revive the transport of proteins and other materials in cells, ameliorating symptoms associated with neurodegeneration.
...
Prof. Gozes is the director of TAU's Adams Super Center for Brain Studies and holds the Lily and Avraham Gildor Chair for the Investigation of Growth Factors.
...
NAP appears to have widespread potential in terms of neuroprotection, says Prof. Gozes, who was recently awarded the Meitner-Humblodt Research Award for her lifelong contribution to the field of brain sciences.
12th INTERNATIONAL CONFERENCE ON ALZHEIMER'S DRUG DISCOVERY
www.worldeventsforum.com, 22 Feb 2007 [cached]
Illana Gozes, PhD, Allon Therapeutics Inc. - Dr. Gozes is a Professor of Clinical Biochemistry, the Lily and Avraham Gildor Chair for the Investigation of Growth factors at Tel Aviv University (TAU) Sackler Faculty of Medicine, where she heads the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology. Professor Gozes serves as the Director of the Adams Super Center for Brain Studies at Tel Aviv University and the Levie-Edersheim-Gitter Institute for Functional Brain Imaging, a collaborative project between Tel Aviv University and the Sourasky Medical Center. Professor Gozes serves or has served as a member (or chair) of several faculty/university/national and international committees including serving now as a member of the Board of Governors of Tel Aviv University, the Tel Aviv University Senate, the Scientific Review Board of the Alzheimer's Drug Discovery Foundation (New York, USA), the Scientific Review Board of the Rett Foundation, member of several Editorial Boards (Peptides, American Journal of Alzheimer's Research and other Dementias, Peptides Research and Therapeutics, Pharmaceutical Drug Design) and Past President of the Israel Society for Neuroscience. Professor Gozes is the Editor-in-Chief of the Journal of Molecular Neuroscience, the Secretary General of the European Neuropeptide Club and the Chair of the Summer Neuropeptide Conference, The International Advisory Committee of VIP PACAP and Related Peptides and Chair of the 2011 Conference.
Dr. Gozes is the scientific founder, Chief Scientific Officer of Allon Therapeutics, where she serves as a member of the Board of Directors. Allon was chosen as the "Most Innovative Development Company" in the New Economy 2010 Pharmaceutical & Healthcare Awards sponsored by New Economy Magazine and won the 2011 Gold Leaf Award as the Early Stage Company of the Year (Health) from BIOTECanada. Prof. Gozes has published extensively in the fields of molecular neuroscience and neuroprotection (>230 publications as cited PUBMED; >280 including a book, book chapters and reviews). She is co-inventor of more than 15 patents and applications (totaling >125 results found in the Worldwide data base for Gozes as an applicant or inventor, including the composition of matter patent on davunetide, Allon's lead compound.) Professor Gozes mentored >50 students toward successful MSc and PhD degrees.
Professor Gozes received a BSc from Tel Aviv University, a PhD from The Weizmann Institute of Science, was a Weizmann Postdoctoral Fellow at Massachusetts Institute of Technology, Research Associate/Visiting Scientist at the Salk Institute and the Scripps Clinic and Research Foundation, a Senior Scientist/Associate Professor at the Weizmann Institute and a distinguished Fogarty-Scholar-in-Residence at the National Institutes of Health (USA).
Leadership | Allon Therapeutics Inc
www.allontherapeutics.com, 24 Dec 2012 [cached]
Illana Gozes, Ph.D. Director Dr. Gozes is a co-founder Allon Therapeutics and a Professor of Clinical Biochemistry, the Lily and Avraham Gildor Chair for the Investigation of Growth factors at Tel Aviv University (TAU) Sackler Faculty of Medicine, where she heads a research lab, and serves or has served as chair of a number of departments and committees. Dr. Gozes has received a number of scientific awards and prizes for her work, and has published extensively in the fields of molecular neuroscience, neuropeptides and neuroprotection. She is co-inventor of more than 15 patents and patent applications, including the composition of matter patent on davunetide, Allon's lead compound. Professor Gozes received a Ph. D. from The Weizmann Institute of Science, and a postdoctoral fellow from Massachusetts Institute of Technology. She was a research associate and visiting scientist at the Salk Institute and the Scripps Clinic and Research Foundation and a Fogarty-Scholar-in-Residence at the National Institutes of Health, USA.
...
Illana Gozes, Ph.D. Chair Dr. Gozes is a co-founder Allon Therapeutics and a Professor of Clinical Biochemistry, the Lily and Avraham Gildor Chair for the Investigation of Growth factors at Tel Aviv University (TAU) Sackler Faculty of Medicine, where she heads a research lab, and serves or has served as chair of a number of departments and committees. Dr. Gozes has received a number of scientific awards and prizes for her work, and has published extensively in the fields of molecular neuroscience, neuropeptides and neuroprotection. She is co-inventor of more than 15 patents and patent applications, including the composition of matter patent on davunetide, Allon's lead compound. Professor Gozes received a Ph. D. from The Weizmann Institute of Science, and a postdoctoral fellow from Massachusetts Institute of Technology. She was a research associate and visiting scientist at the Salk Institute and the Scripps Clinic and Research Foundation and a Fogarty-Scholar-in-Residence at the National Institutes of Health, USA.
...
Professor Fridkin is a leading figure in peptide synthesis and has been collaborating with Professor Gozes on synthetic peptides structure and function and development of peptide-related drugs for over 20 years leading to more than 50 publications and several patents.
Allon granted European patent for learning and memory compound | Allon Therapeutics Inc
www.allontherapeutics.com, 20 Dec 2004 [cached]
Dr. Illana Gozes, an internationally acclaimed neuroscientist is one of three inventors of this new class of novel drugs. Dr. Gozes is CSO and founder of Allon. Allon has exclusive worldwide rights to this granted patent via its license agreements with the U.S. National Institutes of Health and Tel Aviv University.
The compounds covered by the European patent were derived from neuroprotective proteins discovered by Dr. Gozes and her colleagues and identified as Activity Dependent Neuroprotective Protein (ADNP) and Activity Dependent Neurotrophic Factor (ADNF).
Allon’s CEO presenting at BIO CEO conference in NYC, Allon’s founder honoured for neuroscience research | Allon Therapeutics Inc
www.allontherapeutics.com, 2 Dec 2008 [cached]
Prof. Illana Gozes honoured
Allon also announced today that Prof. Illana Gozes, the Company's founder and chief scientist, has been honoured by her peers in Israel for her neuroscience research.
Prof. Gozes was selected as the 2007 recipient of the Tel Aviv University Applied Research Award. The award is given to one faculty member annually for outstanding achievements in applied research exemplified by numerous versatile inventions and patents.
Prof. Gozes was also elected as the President-elect of the Israel Society for Neuroscience to serve a term as President beginning in December 2008. The goal of the Israel Society for Neuroscience is to promote understanding of how the central and peripheral nervous systems operate under normal and pathological conditions.
Prof. Gozes is a professor of clinical biochemistry, the Lily and Avraham Gildor Chair for the Investigation of Growth Factors and the Director of the Adams Super Center for Brain Studies at Tel Aviv University. She is also a member of the Sackler Faculty of Medicine, the editor-in-chief of the Journal of Molecular Neuroscience, and a member or chair of several national and international scientific committees.
Gordon McCauley, President and CEO of Allon, said Prof. Gozes' research achievements include the discovery and development of the novel class of proprietary compounds that is now being evaluated in Allon's clinical trials.
Other People with the name "Gozes":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304